| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7211600 | CPPI CV | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Dec, 2020
(3 years ago) | |
| US6573293 | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb, 2021
(3 years ago) | |
| US7125905 | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb, 2021
(3 years ago) | |
|
US7211600 (Pediatric) | CPPI CV | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Jun, 2021
(2 years ago) | |
|
US6573293 (Pediatric) | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug, 2021
(2 years ago) | |
|
US7125905 (Pediatric) | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug, 2021
(2 years ago) | |
Sutent is owned by Cppi Cv.
Sutent contains Sunitinib Malate.
Sutent has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Sutent are:
- US7211600
- US6573293
- US7125905
- US7211600*PED
- US6573293*PED
- US7125905*PED
Sutent was authorised for market use on 26 January, 2006.
Sutent is available in capsule;oral dosage forms.
Sutent can be used as treatment of protein kinase related disorders, such as gastrointestinal stromal tumors, renal cell carcinoma and advanced pancreatic neuroendocrine tumors, with sunitinib, treatment of gastrointestinal stromal tumor with sunitinib.
The generics of Sutent are possible to be released after 15 August, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-755) | Nov 16, 2020 |
| Pediatric Exclusivity(PED) | May 16, 2021 |
| New Indication(I-639) | May 20, 2014 |
Drugs and Companies using SUNITINIB MALATE ingredient
Market Authorisation Date: 26 January, 2006
Treatment: Treatment of gastrointestinal stromal tumor with sunitinib; Treatment of protein kinase related disorders, such as gastrointestinal stromal tumors, renal cell carcinoma and advanced pancreatic neuroen...
Dosage: CAPSULE;ORAL
SUTENT family patents
